Catalent (NYSE:CTLT) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Catalent (NYSE:CTLTFree Report) in a report released on Tuesday. The brokerage issued a sell rating on the stock.

Several other equities analysts also recently issued reports on the company. Royal Bank of Canada reiterated a sector perform rating and issued a $63.50 price objective on shares of Catalent in a research report on Tuesday, February 20th. UBS Group reiterated a neutral rating and issued a $63.50 price objective (up previously from $58.00) on shares of Catalent in a research report on Tuesday, February 6th. Barclays lifted their price objective on Catalent from $45.00 to $47.00 and gave the company an equal weight rating in a research report on Thursday, January 25th. Finally, Stephens reiterated an equal weight rating and issued a $63.50 price objective on shares of Catalent in a research report on Thursday, April 4th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Catalent has an average rating of Hold and an average target price of $53.14.

View Our Latest Stock Report on CTLT

Catalent Price Performance

Shares of NYSE:CTLT opened at $55.01 on Tuesday. Catalent has a 1-year low of $31.80 and a 1-year high of $60.20. The firm has a market capitalization of $9.96 billion, a PE ratio of -9.02, a PEG ratio of 6.68 and a beta of 1.18. The business’s 50 day moving average is $56.13 and its 200-day moving average is $50.52. The company has a current ratio of 2.51, a quick ratio of 1.77 and a debt-to-equity ratio of 1.37.

Catalent (NYSE:CTLTGet Free Report) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of $0.21 by ($0.36). The company had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.11 billion. Catalent had a negative net margin of 26.61% and a negative return on equity of 2.73%. Sell-side analysts predict that Catalent will post 0.28 earnings per share for the current year.

Institutional Investors Weigh In On Catalent

A number of institutional investors have recently made changes to their positions in CTLT. Lindbrook Capital LLC raised its holdings in Catalent by 79.4% during the first quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock worth $27,000 after acquiring an additional 208 shares in the last quarter. Gladius Capital Management LP bought a new stake in Catalent in the third quarter valued at approximately $28,000. GAMMA Investing LLC bought a new stake in Catalent in the fourth quarter valued at approximately $33,000. Cary Street Partners Investment Advisory LLC raised its stake in Catalent by 1,162.3% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 770 shares of the company’s stock valued at $35,000 after buying an additional 709 shares during the period. Finally, Rakuten Securities Inc. bought a new stake in Catalent in the fourth quarter valued at approximately $46,000.

Catalent Company Profile

(Get Free Report)

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.

Featured Articles

Analyst Recommendations for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.